A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

NCT05619172 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Due to lack of efficacy shown at the time of the interim analysis.

Conditions

Colorectal Cancer

Interventions

DRUG: Nanrilkefusp alfa
DRUG: Cetuximab

Sponsor

SOTIO Biotech AG